PRESS RELEASE published on 06/25/2025 at 18:00, 8 months 27 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV received a transparency notification from Atlas Special Opportunities II, LLC indicating a decrease in shareholding below the threshold. The biopharmaceutical company is focused on therapeutic innovation and clinical research technologies Technology Clinical Research Transparency Notification Biopharmaceutical Oxurion NV
BRIEF published on 06/19/2025 at 08:35, 9 months 4 days ago Oxurion to Acquire Preclinical Microbiology CRO in Toulouse Acquisition Diversification Toulouse Oxurion Microbiology CRO
BRIEF published on 06/19/2025 at 08:35, 9 months 4 days ago Oxurion acquiert une CRO en microbiologie préclinique à Toulouse Acquisition Diversification Toulouse Oxurion CRO En Microbiologie
PRESS RELEASE published on 06/19/2025 at 08:30, 9 months 4 days ago Oxurion ondertekent intentieverklaring voor de voorgenomen overname van een preklinische microbiologie-CRO om zich te diversifiëren en zijn aanwezigheid in de regio Toulouse te versterken Oxurion NV, een biofarmaceutisch bedrijf in Leuven, kondigt intentieovereenkomst voor de overname van onderneming gespecialiseerd in microbiologische diensten aan, ter versterking van expertise en strategie Stratégie Overname Oxurion NV Biofarmaceutisch Microbiologische Diensten
PRESS RELEASE published on 06/19/2025 at 08:30, 9 months 4 days ago Oxurion signs a letter of intent for the planned acquisition of a preclinical microbiology CRO to diversify and strengthen its presence in the Toulouse region Oxurion NV announces LOI to acquire 70% share capital of preclinical microbiology services company. Economic details of the transaction and growth projections disclosed Acquisition Transaction Details Growth Projections Oxurion NV Preclinical Microbiology
PRESS RELEASE published on 06/19/2025 at 08:30, 9 months 4 days ago Oxurion signe une lettre d'intention pour l'acquisition projetée d'une CRO de services précliniques en microbiologie afin de se diversifier et de renforcer sa présence en région toulousaine Oxurion NV signe une lettre d'intention pour l'acquisition de 70% d'une société spécialisée en microbiologie appliquée à la santé humaine et animale, dermocosmétiques et nutraceutiques Acquisition Biopharmaceutique Lettre D'intention Oxurion NV Microbiologie Appliquée
BRIEF published on 06/18/2025 at 18:05, 9 months 4 days ago Oxurion Announces Transparency Notification from Atlas Special Opportunities II LLC Transparency Notification Biopharmaceutical Atlas Special Opportunities Ownership Structure Oxurion
BRIEF published on 06/18/2025 at 18:05, 9 months 4 days ago Oxurion annonce une notification de transparence de la part d'Atlas Special Opportunities II LLC Biopharmaceutique Notification De Transparence Oxurion Opportunités Spéciales Atlas Structure De Propriété
PRESS RELEASE published on 06/18/2025 at 18:00, 9 months 4 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV announces receipt of transparency notification from Atlas Special Opportunities II, LLC regarding shareholding. Company combines therapeutic innovation with technology for clinical research Clinical Research Transparency Notification Biopharmaceutical Belgium Oxurion NV
PRESS RELEASE published on 06/18/2025 at 18:00, 9 months 4 days ago Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC Oxurion NV ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC, verlaagt aandeel tot onder drempel 20%. Biofarmaceutisch bedrijf in Leuven kondigt belangrijke ontwikkeling aan Transparantiekennisgeving Oxurion NV Biofarmaceutisch België Atlas Special Opportunities II LLC
Published on 03/23/2026 at 14:05, 1 hour 27 minutes ago Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Published on 03/23/2026 at 14:00, 1 hour 32 minutes ago BlackBerry AtHoc Advances Command Center for Faster Response and Tighter Control During Critical Operations
Published on 03/23/2026 at 13:05, 2 hours 27 minutes ago SouthGobi Announces Disclosable and Connected Transaction Deferral of Payment Obligations Under Convertible Debenture and Amended and Restated Cooperation Agreement
Published on 03/23/2026 at 12:32, 3 hours ago Sinopec Announced 2025 Annual Results Annual Payout Ratio Reached 81%
Published on 03/23/2026 at 12:30, 3 hours 2 minutes ago Digi Power X to Announce 2025 Year End Financial Results on March 31st
Published on 03/23/2026 at 15:05, 27 minutes ago Heidrick & Struggles Launches Heidrick Immersive, an AI-Enhanced Platform for Observing Leadership in Motion
Published on 03/23/2026 at 14:30, 1 hour 2 minutes ago Solvias Earns EcoVadis Bronze Medal, Ranking in Top 35% of Companies for Sustainability Performance
Published on 03/23/2026 at 14:30, 1 hour 2 minutes ago Belvilla Expands in Germany with Hambachtal Holiday Park in Oberhambach
Published on 03/23/2026 at 14:24, 1 hour 8 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 03/23/2026 at 08:10, 7 hours 22 minutes ago Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 20 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 20 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 21 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 21 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA